Pages that link to "Q54044592"

The following pages link to Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. (Q54044592):

Displaying 44 items.

• Advanced ovarian cancer: what should be the standard of care? (Q27852053) (← links)
• Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group (Q30428523) (← links)
• Docetaxel for treatment of solid tumours: a systematic review of clinical data (Q30986509) (← links)
• A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors (Q33339062) (← links)
• Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study (Q33365485) (← links)
• Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer (Q33380764) (← links)
• Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxel-carboplatin-based neoadjuvant chemotherapy (Q33599194) (← links)
• Taxane pathway (Q34390370) (← links)
• Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer (Q34636703) (← links)
• Epithelial ovarian cancer (Q34677827) (← links)
• Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis (Q34826546) (← links)
• Optimizing primary chemotherapy in ovarian cancer (Q35213229) (← links)
• Drug resistance reversal--are we getting closer? (Q35577444) (← links)
• Docetaxel: an alternative taxane in ovarian cancer (Q35602177) (← links)
• Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies (Q35602185) (← links)
• Docetaxel: promising and novel combinations in ovarian cancer (Q35602190) (← links)
• Docetaxel in the management of ovarian cancer (Q36118370) (← links)
• The role of maintenance therapy and novel taxanes in ovarian cancer (Q36388068) (← links)
• A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. (Q36696463) (← links)
• Docetaxel for the post-surgery treatment of patients with node-positive breast cancer (Q36823602) (← links)
• Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer (Q37082453) (← links)
• Pharmaceutical management of ovarian cancer : current status (Q37139726) (← links)
• The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. (Q37182159) (← links)
• Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer (Q37230157) (← links)
• Single institutional experience of the treatment of angiosarcoma of the face and scalp (Q37233716) (← links)
• Taxanes: their impact on gynecologic malignancy (Q37692801) (← links)
• The microtubule as a breast cancer target (Q37791482) (← links)
• Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study (Q40304292) (← links)
• Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. (Q40363722) (← links)
• A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. (Q40463049) (← links)
• Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum (Q40543982) (← links)
• Human mutations that confer paclitaxel resistance. (Q41769659) (← links)
• Chemotherapy for ovarian cancer: yesterday, today and tomorrow (Q42564045) (← links)
• Single nedaplatin treatment as salvage chemotherapy for platinum/taxane‐resistant/refractory epithelial ovarian, tubal and peritoneal cancers (Q42953685) (← links)
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study (Q44315213) (← links)
• Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin (Q44473101) (← links)
• A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer (Q44533927) (← links)
• Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. (Q46489542) (← links)
• Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors (Q50736135) (← links)
• Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer (Q51746755) (← links)
• Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients (Q56785964) (← links)
• Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01 (Q79322354) (← links)
• Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer (Q84474115) (← links)
• Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes (Q91911694) (← links)